New Two-Step Alzheimer’s Test Combines Retinal Imaging and Blood Biomarkers
Circular Genomics and Vitazi.ai have announced a powerful new partnership to revolutionize early detection of Alzheimer’s disease, unveiling a cutting-edge two-step diagnostic workflow that could transform patient outcomes across the United States.
The innovative approach starts with a non-invasive AI-powered retinal scan conducted in primary care or optometry offices, screening patients for early risk signs. This is immediately followed by a blood test analyzing circular RNA biomarkers to confirm the disease’s presence at a molecular level. The technique promises faster, more precise detection of Alzheimer’s long before symptoms appear.
Why This Matters Now for Patients and Healthcare Providers
Current diagnostics often lag years behind the onset of Alzheimer’s symptoms, limiting treatment effectiveness. This new workflow targets that crucial gap by pairing easily accessible retinal imaging with sensitive molecular blood tests. The system offers a scalable, cost-effective screening path designed to facilitate earlier intervention when therapies work best.
Paul Sargeant, CEO of Circular Genomics, emphasized the broad potential impact, saying the partnership expands their platform beyond specialty clinics into primary care settings nationwide. Meanwhile, Jeremy Stueven, CEO of Vitazi.ai, described the collaboration as “combining complementary data modalities that reflect different dimensions of human biology,” highlighting the integration of retinal structure and blood biomarker data through advanced machine learning.
How the Technology Works
The backbone of the test is a sophisticated multimodal AI model that merges two distinct but complementary data types: the structural and vascular features of the retina extracted by Vitazi.ai’s platform, and cell-free circular RNA biomarkers identified in blood by Circular Genomics. Circular RNAs are remarkably stable and brain-enriched, offering a unique molecular window into neurodegenerative disease biology beyond traditional protein-based tests.
This integration poses a complex data challenge requiring advanced machine learning methods to accurately interpret the combined signals. The result is a unified predictive system with unprecedented accuracy and early detection capability.
Implications for Montana and Nationwide Healthcare
For Montana and other US states, this breakthrough means easier access to early Alzheimer’s screening—especially critical in rural areas where advanced neurology services are scarce. Primary care providers could soon offer routine retinal scans to flag at-risk patients, followed by blood testing to confirm diagnosis. This opens new doors for better clinical management and potentially accelerates enrollment in clinical trials for emerging therapies.
Nikolaos Mellios, Chief Scientific Officer at Circular Genomics, noted the broader significance: “This fundamentally changes how we model and measure neurodegenerative diseases, extending beyond Alzheimer’s to impact the entire field of precision neurology.”
Next Steps and What to Watch For
Circular Genomics and Vitazi.ai are currently advancing development and validation of their multimodal screening system across diverse patient populations. Healthcare systems, pharmaceutical companies, and clinicians are watching closely, as this platform may soon become the new frontline tool against Alzheimer’s, spearheading earlier detection and more effective treatments nationwide.
As disease-modifying Alzheimer’s therapies prove more effective when administered early, this scalable new approach holds promise for reducing the huge personal and economic toll of the disease, including for Montana’s aging population.
The urgency is clear: faster, accessible, and accurate early diagnosis could reshape Alzheimer’s care paradigms forever—changing countless lives across Montana and the US starting today.
